<! –

->

Analysts expect Anavex Life Sciences Corp. (NASDAQ: AVXL) publishes EPS of -0.10 USD on December 10th. They expect EPS of US $ 0.02, or 16.67% over EPS of -0.12 last quarter. After having already reached a -0.06 $ EPS, badysts Anavex Life Sciences Corp. earnings per share growth of 66.67%. The stock decreased by 5.10% or $ 0.13 during the last trading session to $ 2.42. Approximately 156,888 shares were exchanged. Anavex Life Sciences Corp. (NASDAQ: AVXL) has decreased 46.96% since November 6, 2017 and is on the decline. It underperformed the S & P500 by 62.58%.

Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company, is developing drug candidates for the treatment of Alzheimer's disease, other central nervous system diseases, pain and various cancers. The company has a market capitalization of $ 109.94 million. The company's leading drug candidates include ANAVEX 2-73, which has completed Phase IIa clinical trials for the treatment of Alzheimer's disease; and in preclinical clinical trials to treat Parkinson's disease, epilepsy, Rett's syndrome, Angelman's syndrome, multiple sclerosis and Fragile X syndrome. He currently has negative gains. The Company's preclinical drug candidates include ANAVEX 3-71 for the treatment of Alzheimer's disease; ANAVEX 1-41, a sigma-1 agonist; ANAVEX 1037 for the treatment of prostate cancer; and ANAVEX 1066, a sigma-1 / sigma-2 mixed ligand for the treatment of neuropathic and visceral pain.

The most recent news from Anavex Life Sciences Corp. (NASDAQ: AVXL) was published by: Nasdaq.com, which published: "The first patient enrolled in the Anavex Life Sciences Phase 2 clinical trial of ANAVEX®2-73 for the treatment of Parkinson's disease … October 30, 2018, also Seekingalpha.com with their article: "PayPal's 8% advance on pre-market winners" published Oct. 19, 2018, Streetinsider.com released: "Pre-Open Movers 10/19: (AVXL) (PYPL) (PG) higher; (MACK) (OZK) (AKTS) Lower (more …) "October 19, 2018. More interesting news about Anavex Life Sciences Corp. (NASDAQ: AVXL) were published by: Seekingalpha.com and their article: "The FDA approves Anavex IND in Life Sciences for the ANAVEX2-73 Phase 2 Trial; shares before 34% pre-market, "published October 19, 2018, as well as in the article Seekingalpha.com titled:" Registration underway in the mid-stage study of Anavex 2-73 in related dementia Parkinson's disease; shares up 10% before commercialization "with the publication: October 30, 2018.

By Dolores Ford